The pharma will work with Triana Biomedicines on molecular glue degraders. Elsewhere, Akeso raised $250 million and a MASH drug developer got a well-known board chair.

The amount surpassed the firm’s targets, allowing it to increase the size and number of company financings it plans to do in the future.

Biosimilar competition is expected in early January for the company’s second highest-selling drug, putting greater focus on newer products' market trajectory.

Harris aims to broaden some IRA provisions, including Medicare’s power to negotiate drug prices, while Trump has publicly endorsed a more industry-friendly approach.

Data Validation and Compliance: The Sapio LIMS and ELN ensure adherence to the FDA and EMA-guided IGX assay validation approach, providing for monitoring and reporting on cut points, sensitivity, ...

Alimentiv, a full-service GI CRO and pioneer in IBD medical imaging solutions since 1986, is excited to announce the expansion of its partnership with Satisfai Health, a leader in AI medical solutions ...